Andrew Parece and Urs Wiedemann published an article in the April issue of Pharmaceutical Executive. The authors discuss outcomes-based, risk-sharing agreements as one approach to change the dialogue between manufacturers and payers, from price to value. To read the article, click the link below.
Evaluating Medicare Stars for cardiovascular disease patients
Considering that cardiovascular disease (CVD) remains the leading cause of death in the United States, particularly affecting the growing population of...